Admedus Limited
(ASX:AHZ) says it is about to commence vaccine dosing for its Herpes Simplex 2 study.
Over half of the required 40 participants have been approved and the first of a series of three therapeutic injections is due to happen by the end of the month.
It is hoped trial will prove the drug is well tolerated in people with HSV-2. Currently, there is no cure, simply a daily treatment that can reduce symptoms.
Admedus has enjoyed recent success with its Cardio Cel, a regenerative cardio vascular tissue technology and recently indicated it may need to raise additional funding for future activies.
Admedus reported a net loss of $10.7 million for the first half of the 2015 financial year.
